|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Single-port laparoscopic cholecystectomy vs standard laparoscopic cholecystectomy:A non-randomized,agematched single center trial显示文摘AIM: To compare the safety of single-port laparoscopic cholecystectomies with standard four-port cholecystectomies.METHODS: Between January 2011 and December 2012 datas were gathered from 100 consecutive patients who received a single-port cholecystectomy. Patient baseline characteristics of all 100 single-port cholecystectomies were collected(body mass index, age, etc.) in a database. This group was compared with 100 age-matched patients who underwent a conventional laparoscopic cholecystectomy in the same period. Retrospectively, per- and postoperative data were added. The two groups were compared to each other using independent t-tests and χ2-tests, P values below 0.05 were considered significantly different.RESULTS: No differences were found between both groups regarding baseline characteristics. Operating time was significantly shorter in the total single-port group(42 min vs 62 min, P < 0.05); in procedures performed by surgeons the same trend was seen(45 min vs 59 min, P < 0.05). Peroperative complications between both groups were equal(3 in the single-port group vs 5 in the multiport group; P = 0.42). Although not significant less postoperative complications were seen in the single-port group compared with the multiport group(3 vs 9; P = 0.07). No statistically significant differences were found between both groupswith regard to length of hospital stay, readmissions and mortality. CONCLUSION: Single-port laparoscopic cholecystectomy has the potential to be a safe technique with a low complication rate, short in-hospital stay and comparable operating time. Single-port cholecystectomy provides the patient an almost non-visible scar while preserving optimal quality of surgery. Further prospective studies are needed to prove the safety of the single-port technique. | Yoen TK van der Linden Koop Bosscha Hubert A Prins Daniel J Lips | 2015 | World Journal of Gastrointestinal Surgery2015，7，8： | 2 |
| 2 | Phase Ⅱ study of docetaxel,cisplatin and capecitabine as preoperative chemotherapy in resectable gastric cancer显示文摘AIM To investigate the feasibility of preoperative docetaxel,cisplatin and capecitabine(DCC) in patients with resectable gastric cancer.METHODS Patients with resectable gastric cancer fulfilling the inclusion criteria,were treated with 4 cycles of docetaxel(60 mg/m2),cisplatin(60 mg/m2) and capecitabine(1.875 mg/m2 orally on day 1-14,two daily doses) repeated every three weeks,followed by surgery.Primary end point was the feasibility and toxicity/safety profile of DCC,secondary endpoints were pathological complete resection rate and pathological complete response(p CR) rate.RESULTS All of the patients(51) were assessable for the feasibility and safety of the regimen.The entire preoperative regimen was completed by 68.6% of the patients.Grade Ⅲ/Ⅳ febrile neutropenia occurred in 10% of all courses.Three patients died due to treatment related toxicity(5.9%),one of them(also) because of refusing further treatment for toxicity.Of the 45 patients who were evaluable for secondary endpoints,four developed metastatic disease and 76.5% received a curative resection.In 3 patients a p CR was seen(5.9%),two patients underwent a R1 resection(3.9%).CONCLUSION Four courses of DCC as a preoperative regimen for patients with primarily resectable gastric cancer is highly demanding.The high occurrence of febrile neutropenia is of concern.To decrease the occurrence of febrile neutropenia the prophylactic use of granulocyte colonystimulating factor(G-CSF) should be explored.A curative resection rate of 76.5% is acceptable.The use of DCC without G-CSF support as preoperative regimen in resectable gastric cancer is debatable. | Anneriet E Dassen Nienke Bernards Valery EPP Lemmens Yes AJ van de Wouw Koop Bosscha Geert-Jan Creemers Hans JFM Pruijt | 2016 | World Journal of Gastrointestinal Surgery2016，8，10： | 1 |
| 3 | The lymph node ratio as a prognostic factor for gastric cancer显示文摘 | Stijn D. Nelen Liza N. van Steenbergen Anneriet E. Dassen Anneke A.M. van der Wurff Valery E.P.P. Lemmens Koop Bosscha | 2013 | Acta Oncologica2013，，8： | 1 |
| 4 | 麻醉技术对结肠癌患者术后生存期的影响:文献综述显示文摘对于潜在可根治的结肠癌,手术切除是核心治疗方式。尽管肉眼看不见,但大多数患者术中都会残留一些癌细胞。而手术本身所引起的免疫抑制也会影响到肿瘤复发和术后生存。相较于阿片类麻醉剂,区域阻滞麻醉或椎管内麻醉(如硬膜外麻醉)或可通过减少应激和降低阿片类麻醉剂的用量,减轻对免疫功能的抑制作用。研究显示,区域阻滞麻醉可降低乳腺癌和前列腺癌的复发率,从而印证了这一假设。然而对于结肠癌,相关研究结果却不尽一致。本文对所有探讨硬膜外麻醉与结肠癌手术患者生存相关性的研究进行了综述。 | F.Jeroen Vogelaar Daan J.Lips Frank R.C.van Dorsten Valery E.Lemmens Koop Bosscha | 2016 | Gastroenterology Report2016，4，1： | 0 |
| 5 | Pelvic sepsis after stapled hemorrhoidopexy显示文摘Stapled hemorrhoidopexy is a surgical procedure used worldwide for the treatment of grade Ⅲ and Ⅳ hemorrhoids in all age groups. However, life-threatening complications occur occasionally. The following case report describes the development of pelvic sepsis after stapled hemorrhoidopexy. A literature review of techniques used to manage major septic complications after stapled hemorrhoidopexy was performed. There is no standardized treatment currently available. Stapled hemorrhoidopexy is a safe, effective and time-efficient procedure in the hands of experienced colorectal surgeons. | Remco JA van Wensen Maarten H van Leuken Koop Bosscha | 2008 | World Journal of Gastroenterology2008，14，38： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员